Rivera NV, et al. High-density genetic mapping identifies new susceptibility variants in sarcoidosis phenotypes and shows genomic-driven phenotypic differences. Am J Respir Crit Care Med. 2016;193(9):1008–22.
Article CAS PubMed PubMed Central Google Scholar
Grunewald J, et al. Immunogenetics of disease-causing inflammation in sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):19–35.
Article CAS PubMed Google Scholar
Newman LS, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.
Cozier YC, et al. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011;139(1):144–50.
Rybicki BA, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41.
Article CAS PubMed Google Scholar
Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020;26(5):527–34.
Article PubMed PubMed Central Google Scholar
Sève P, et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells. 2021;10(4).
Cacoub P, et al. Cardiac sarcoidosis: a long term follow up study. PLoS One. 2020;15(9):e0238391.
Hamzeh N, et al. Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol. 2015;12(5):278–88.
Uusimaa P, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008;10(6):760–6.
•• Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):305–23. HRS Guidelines for cardiac sarcoidosis.
Webb M, et al. Cardiac involvement in sarcoidosis deaths in Wayne County, Michigan: a 20-year retrospective study. Acad Forensic Pathol. 2018;8(3):718–28.
Article PubMed PubMed Central Google Scholar
Iwai K, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–6.
Matsui Y, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–69.
Article CAS PubMed Google Scholar
Iwai K, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26–31.
Okada DR, et al. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol. 2018;25(4):1136–46.
•• Terasaki F, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis - digest version. Circ J, 2019;83(11):2329–2388. JCS Guidelines for cardiac sarcoidosis.
Judson MA, et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.
Nagao S, et al. Electrocardiographic abnormalities and risk of developing cardiac events in extracardiac sarcoidosis. Int J Cardiol. 2015;189:1–5.
Crouser ED, et al. Diagnosis and detection of sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(8):e26–e51.
Ohira H, et al. Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis. ERJ Open Res. 2022;8(2).
Kurmann R, Mankad SV, Mankad R. Echocardiography in Sarcoidosis. Curr Cardiol Rep. 2018;20(11):118.
Darlington P, et al. Diagnostic approach for cardiac involvement in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):11–7.
PubMed PubMed Central Google Scholar
Di Stefano C, et al. Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis. BMC Cardiovasc Disord. 2020;20(1):21.
Article PubMed PubMed Central Google Scholar
Schouver ED, et al. Early detection of cardiac involvement in sarcoidosis with 2-dimensional speckle-tracking echocardiography. Int J Cardiol. 2017;227:711–6.
Bera D, et al. Serum angiotensin converting enzyme, erythrocyte sedimentation rate and high sensitive-C reactive protein levels in diagnosis of cardiac sarcoidosis- where do we stand? Indian Pacing Electrophysiol J. 2020;20(5):184–8.
Article PubMed PubMed Central Google Scholar
Handa T, et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(1):27–35.
Kiko T, et al. A multiple biomarker approach in patients with cardiac sarcoidosis. Int Heart J. 2018;59(5):996–1001.
Article CAS PubMed Google Scholar
Kobayashi Y, et al. Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis. ESC Heart Fail. 2021;8(6):5282–92.
Article PubMed PubMed Central Google Scholar
Kolluri N, et al. Routine laboratory biomarkers as prognostic indicators of cardiac sarcoidosis outcomes. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(3):e2022023.
PubMed PubMed Central Google Scholar
Markatis E, et al. Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med. 2020;21(3):321–38.
Freeman AM, et al. Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Cardiol. 2013;112(2):280–5.
Mehta D, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426–35.
Padala SK, et al. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol. 2017;227:565–70.
Elwazir MY, Bois JP, Chareonthaitawee P. Utilization of cardiac imaging in sarcoidosis. Expert Rev Cardiovasc Ther. 2022;20(4):253–66.
Article CAS PubMed Google Scholar
Smedema JP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–90.
•• Greulich S, et al. Hybrid cardiac magnetic resonance/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis. JACC Cardiovasc Imaging. 2022;15(3):445–456. Study showing diagnostic utility in hybrid CMR/FDG-PET in evaluation of cardiac sarcoidosis.
Aitken M, et al. Diagnostic accuracy of cardiac MRI versus FDG PET for cardiac sarcoidosis: a systematic review and meta-analysis. Radiology. 2022;304(3):566–79.
Greulich S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–11.
Yoshida A, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail. 2013;15(2):166–75.
Kouranos V, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10(12):1437–47.
Sobol I, et al. Assessment of unexplained cardiomyopathy: clinical utility of delayed-enhancement cardiac magnetic resonance compared to endomyocardial biopsy. J Am Coll Cardiol. 2012;59(13, Supplement):E1553.
Flamée L, et al. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis. Eur Radiol. 2020;30(7):3702–10.
Coleman GC, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10(4):411–20.
Hulten E, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9(9):e005001.
Article PubMed PubMed Central Google Scholar
Crouser ED, et al. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109–12.
Article PubMed PubMed Central Google Scholar
Greulich S, et al. Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging. 2016;9(11).
Dill T. Contraindications to magnetic resonance imaging. Heart. 2008;94(7):943–8.
Article CAS PubMed Google Scholar
Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET imaging in sarcoidosis. Semin Nucl Med. 2013;43(6):404–11.
Soussan M, et al. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med. 2014;39(2):e146–59.
Comments (0)